Acalabrutinib
- Generic Name
- Acalabrutinib
- Brand Names
- Calquence
- Drug Type
- Small Molecule
- Chemical Formula
- C26H23N7O2
- CAS Number
- 1420477-60-6
- Unique Ingredient Identifier
- I42748ELQW
- Background
To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others.
...
- Indication
Acalabrutinib is currently indicated for the treatment of adult patients with Mantle Cell Lymphoma (MCL) who have received at least one prior therapy. It has also been recently approved for chronic lymphocytic leukemia and small lymphocytic lymphoma.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma (MCL), Small Lymphocytic Lymphoma
- Associated Therapies
- -
Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 4
- Registration Number
- NCT04657094
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
World Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 Treatments
- Conditions
- Interventions
- First Posted Date
- 2020-12-01
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- The University of The West Indies
- Target Recruit Count
- 100
- Registration Number
- NCT04647669
- Locations
- 🇯🇲
Univeristy of the West Indies, Kingston, Jamaica
Study of Acalabrutinib and Tafasitamab in MZL Patients
- Conditions
- Interventions
- First Posted Date
- 2020-11-30
- Last Posted Date
- 2024-10-24
- Target Recruit Count
- 26
- Registration Number
- NCT04646395
- Locations
- 🇦🇹
University of Wien, Wien, Austria
🇮🇹ASST Spedali Civili di Brescia, Brescia, Italy
🇮🇹Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano, Italy
AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT04630756
- Locations
- 🇬🇧
Research Site, Plymouth, United Kingdom
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 45
- Registration Number
- NCT04626791
- Locations
- 🇺🇸
Ochsner NCI Community Oncology Research Program, New Orleans, Louisiana, United States
🇺🇸Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin, United States
🇺🇸Mount Sinai Hospital, New York, New York, United States
Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia
- Conditions
- Interventions
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Target Recruit Count
- 63
- Registration Number
- NCT04624906
- Locations
- 🇨🇦
McGill University Health Centre, Montréal, Quebec, Canada
🇨🇦QEII Health Sciences Centre, Halifax, Nova Scotia, Canada
🇨🇦CHU de Quebec - University Laval, Laval, Quebec, Canada
Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL
- Conditions
- Interventions
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Jennifer R. Brown, MD, PhD
- Target Recruit Count
- 60
- Registration Number
- NCT04624633
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.
- First Posted Date
- 2020-10-27
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 260
- Registration Number
- NCT04604067
- Locations
- 🇮🇹
Ospedale Papa Giovanni XXIII, Bergamo, Italy
🇮🇹Azienda Ospedaliera Universitaria Maggiore della Carita di Novara, Novara, Italy
🇮🇹Policlinico Agostino Gemelli, Roma, Italy
Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-09-28
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 54
- Registration Number
- NCT04566887
- Locations
- 🇨🇦
BC Cancer Agency, Vancouver, British Columbia, Canada
🇨🇦QEII Health Sciences Centre, Halifax, Nova Scotia, Canada
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
- Conditions
- Interventions
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04560322
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.